brozopent sodium

Brozopent sodium (also known as brozopentyl sodium, brozopine, or BZP) is a novel small molecule drug developed for the treatment of acute ischemic stroke. Derived from 3-n-butylphthalide (NBP), a compound originally isolated from celery seeds, brozopent sodium was designed to improve upon the efficacy and safety profile of NBP. It acts primarily as an inhibitor of 12/15-lipoxygenase (12/15-LOX, specifically ALOX15B / 15-LOX-2), thereby mitigating oxidative stress, neuroinflammation, and neuronal damage associated with cerebral ischemia. Brozopent sodium was originally developed by Zhengzhou University and subsequently licensed to Zhejiang Ausun Pharmaceutical and Hangzhou Ausia Biological Technology for clinical development. It is currently being evaluated in Phase II clinical trials in China as an intravenous injection for patients with acute ischemic stroke within 48 hours of symptom onset.

Other names

brozopentyl sodiumbrozopinesodium (±)-5-bromo-2-(α-hydroxypentyl)benzoatesodium 5-bromo-2-(1-hydroxypentyl)benzoatesodium 5-bromo-2-(alpha-hydroxypentyl)benzoate布罗佐喷钠注射用布罗佐喷钠